Breaking Down SG&A Expenses: Pfizer Inc. vs Alpine Immune Sciences, Inc.

A Tale of Two Companies: SG&A Expenses in the Pharmaceutical Industry

In the ever-evolving pharmaceutical landscape, understanding the financial dynamics of industry giants and emerging players is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Pfizer Inc. and Alpine Immune Sciences, Inc. from 2014 to 2023.

Pfizer, a stalwart in the industry, consistently reported SG&A expenses averaging around $14 billion annually. Despite fluctuations, their expenses remained relatively stable, reflecting their robust market presence and strategic investments. In contrast, Alpine Immune Sciences, a burgeoning biotech firm, exhibited a remarkable growth trajectory. Their SG&A expenses surged by nearly 872% over the decade, from approximately $2.3 million in 2014 to $22 million in 2023.

This stark contrast highlights the differing scales and strategies of established versus emerging companies, offering insights into their operational priorities and market strategies.